Wird geladen...
Effect of renal impairment on the pharmacokinetics and safety of axitinib
BACKGROUND: Axitinib, an inhibitor of vascular endothelial growth factor (VEGF) receptors, is approved as second-line treatment for advanced renal cell carcinoma (RCC). Agents targeting the VEGF pathway may induce renal toxicities, which may be influenced by pre-existing renal dysfunction. OBJECTIVE...
Gespeichert in:
| Veröffentlicht in: | Target Oncol |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5568082/ https://ncbi.nlm.nih.gov/pubmed/26400730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-015-0389-2 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|